• iPSC Cardiomyocytes Differentiation
    • Drug Discovery & Disease Modeling
    • cTnT, SMA, MLC2A, & MLC2V
    iPSC Cardiomyocytes Differentiation

Cardiomyocytes Differentiation (Ventricular & Atrial)

We provide top-quality service for the directed differentiation of iPSCs into cardiomyocytes using our efficient induction protocol and reagents. We deliver ready-to-use, functional ventricular and atrial cardiomyocytes that are desirable in vitro models for high-content toxicity and drug screening, and cell regeneration research. We deliver receive feasible and physiologically relevant alternatives to embryonic stem cells, primary cells, and animal models. 

  • High-quality atrial and ventricular cardiomyocytes
  • Biomarkers:
    • cTNT, alpha-SMA, MLC2A, and MLC2V; video of beating cells
  • We can generate differentiated cardiomyocytes from iPSC derived from healthy or disease patient samples
  • Fast turnaround: 2 weeks
  • GMP iPSC Differentiation Services Available >> Learn More 

Get iPSCs to genetically modify and further differentiate into immune cells? We offer fully customizable iPSC generation from human or non-human tissue samples, and our genome editing experts can use CRISPR or TARGATT™  to genetically alter the iPSCs to fit your project requirements. If you need to expedite your experimental timeline, ASC also offers off-the-shelf cardiomyocytes. Contact us today to find the best solution for your projects.

youtube icon Beating iPSC-Derived Cardiomyocytes - Video 1| Applied StemCell, Inc.

youtube icon Beating iPSC-Derived Cardiomyocytes - Video 2 | Applied StemCell, Inc.

Products and Services
Technical Details

iPSC Differentiation to Cardiomyocytes

 

Timelines: 4-6 weeks

  1. Recovery, Expansion and Validation of iPSCs/ESCs: estimated 3 weeks
  2. Cardiomyocytes Differentiation: estimated 2-4 weeks
  3. Characterization of differentiated cells by immunocytochemical (ICC) staining: 2 biomarkers (cTNT; SMA): estimated 2-4 days
Case Studies

Case Study 1:

Characterization Of Ventricular and Atrial Cardiomyocytes 

Atrial and Ventricular Cardiomyocytes

Figure 1. Immunostaining of iPSC-derived ventricular and atrial cardiomyocytes for cardiomyocyte-specific biomarkers.
Cardiomyocytes, differentiated from Applied StemCell’s control iPSC line, ASE-9211 were stained with cardiomyocyte markers, MLC2A and MLC2V.

Support Materials
Google